High-dose methotrexate for primary CNS lymphoma in the elderly

Area of Science:

• Neuro-oncology
• Geriatric Medicine
• Clinical Pharmacology

Background:

• Primary central nervous system lymphoma (PCNSL) predominantly affects individuals in their sixth and seventh decades.
• Optimal treatment strategies for elderly patients with PCNSL require careful consideration of efficacy and tolerability.

Purpose of the Study:

• To evaluate the efficacy and tolerability of high-dose methotrexate (HDMTX) in elderly patients diagnosed with PCNSL.
• To assess treatment response rates and overall survival in this specific patient demographic.

Main Methods:

• Retrospective review of ten consecutive elderly patients (median age 72.5 years) with histologically confirmed PCNSL.
• Treatment administered was high-dose methotrexate (HDMTX).
• Toxicity and response were monitored and recorded.

Main Results:

• HDMTX was well-tolerated, with no grade 4 toxicity or febrile neutropenia observed.
• Common toxicities included grade 3 nausea (1 patient), grade 2 mucositis (2 patients), and grade 2 elevated liver transaminases (2 patients).
• An overall response rate of 90% was achieved (6 complete responses, 3 partial responses), with a median overall survival of 36 months.

Conclusions:

• High-dose methotrexate (HDMTX) demonstrates favorable tolerability in elderly patients with PCNSL.
• The efficacy, in terms of response rates and survival, is comparable to other established treatments like chemotherapy and radiotherapy.
• HDMTX represents a viable and effective treatment option for older adults with primary central nervous system lymphoma.